Skip to content
Search

Latest Stories

PDA investigates Boots pharmacists' pension entitlement concerns

PDA investigates Boots pharmacists' pension entitlement concerns

WBA recently moved Boots pension scheme to L&G in a £4.8 billion deal

The Pharmacists’ Defence Association (PDA) is probing major concerns arising from Boots' communications to pharmacists regarding the company's recently announced pension arrangements.


In November, Walgreens Boots Alliance (WBA), the parent company of Boots, transferred the Boots employees' pension scheme to the financial service provider Legal and General (L&G) in a £4.8 billion deal.

Boots notified staff that terms allowing an unreduced pension from age 60 have ceased immediately, following its agreement with L&G.

The PDA highlighted member concerns regarding Boots management's announcement that an unreduced pension from the age of 60 is a discretionary benefit and not guaranteed under the Boots Pension Scheme (BPS), contrary to some members' assumptions.

On December 7, the PDA communicated with affected members—those possessing pension benefits in the BPS, a final salary scheme closed to new entrants in 2010—explaining that the winding up of closed final salary schemes and securing benefits through an insurance policy is a standard procedure.

"Discretionary benefits are not protected unless explicitly included in the rules during the commencement of the winding-up process and buy-in," the PDA wrote.

PDA Union National Officer Paul Moloney said that his team has been evaluating various pieces of information, with a particular focus on the Trust Deed and Rules, which are deemed the definitive documents.

Moloney emphasised that these documents do describe the normal retirement age as 65. “However, we have also seen individual benefit statements from those members kind enough to send them to us. There is no doubt these communicate that a full pension is payable at 60,” he added.

"No mention is made that this is solely at the discretion of the trustees, and importantly, there is no indication that individuals should not rely on this arrangement still being in place upon their retirement,” he added.

Moloney said, "If benefit statements had included words to this effect, we would reluctantly have concluded that nothing could be done to safeguard the unreduced pension at 60. However, based on our examination, such language is absent."

"Our considered view, emphasising the information available to date, suggests a potential matter for resolution by the Pensions Ombudsman.”

However, the PDA advised members against taking additional steps, such as making a claim, pending further investigations by the PDA to determine whether the evidence supports the company's position.

"If not available, we will guide members on the steps to utilise the disputes procedure before filing complaints with the Ombudsman,” Moloney said in the letter.

The PDA plans to provide members with an update by the end of next week.

Boots and the Trustees of the Boots Pension Scheme announced an insurance transaction for increased certainty and security, according to the company.

“In the customary review, various pension options previously at the Trustee's discretion were assessed. Insured options, like death benefits for eligible dependants, were retained, while discretionary choices such as enhanced early retirement were discontinued,” Boots added.

In November, Boots closed three additional stores as part of its ongoing initiative to shutter 300 stores across the UK in the next 12 months.

More For You

NHS pharmacy funding not enough 2025: £3.073B deal with £1.99B gap fuels reform debate.

Funding alone isn’t going to be enough to save community pharmacy

Photo credit: gettyimages

New funding contract ‘not enough’ to release the sector from financial blackhole

After almost a year without an agreement, a new funding contract for community pharmacy was finally announced yesterday (31 March).

The settlement raises the baseline annual funding for the Community Pharmacy Contractual Framework (CPCF) in 2025/26 to £3.073 billion, with an additional £215 million secured to continue Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Pharmacy First: Government confirms £215 million boost to realise its full potential

From April 2025, the consultation fee for Pharmacy First Minor Illness and Clinical Pathways will rise from £15 to £17.

‘Pharmacy First hasn't realised its full potential,’ says Stephen Kinnock

Health Minister Stephen Kinnock has acknowledged that Pharmacy First has huge potential, noting that the service “hasn't realised its full potential.”

As part of efforts to enhance the service, Kinnock yesterday (30) announced £215 million in additional funding for Pharmacy First and other Primary Care Access Recovery Plan services.

Keep ReadingShow less
Free morning-after pill at pharmacies to end postcode lottery for patients

Pharmacy technicians will be allowed to supply of drospirenone for contraception under PGD,

gettyimages

Pharmacy contract: Free morning-after pill to be available at pharmacies soon

The UK government has announced that, for the first time ever, the ‘morning-after pill’ or emergency contraceptive pill will be available free of charge at pharmacies on the NHS, ending the postcode lottery women face in accessing the medicine and reducing inequalities.

The Department of Health and Social Care (DHSC) has confirmed a record £3.073 billion funding package for community pharmacies in 2025/26, alongside an additional £215 million to sustain Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Royal College status: The PDA calls for ‘meaningful and collaborative dialogue’

The profession’s success will depend on collaboration across all sectors, says PDA.

gettyimages

Royal College vote: Less than 7% of GB pharmacists in favour, says PDA

The Pharmacists’ Defence Association (PDA) has criticised the Royal Pharmaceutical Society (RPS) for moving too quickly to a ballot on its proposed transition to a Royal College, arguing that it resulted in low participation from pharmacists in Great Britain.

Announcing the results of the special resolution vote, the RPS said that the outcome was a “clear mandate” in favour of the transformative change.

Keep ReadingShow less
RPS Wales calls for urgent investment in pharmacy workforce at Senedd meeting

Third from the left: Eluned Morgan, First Minister of Wales

Photo credit: RPS

Invest in pharmacy workforce: RPS Wales urges Senedd members

Members of the Senedd (MSs) were briefed on the increasing pressures facing pharmacy teams and the urgent need for action to support their health and wellbeing at an event hosted by the Royal Pharmaceutical Society (RPS) Wales.

The event, held on Wednesday, brought together MSs, including first minister Eluned Morgan, to discuss the findings of RPS’ latest Workforce Wellbeing Survey.

Keep ReadingShow less